[CARA] Cara Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 135.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 9.97 Change: 0.77 (8.37%)
Ext. hours: 10.13 Change: 0.16 (1.6%)

chart CARA

Refresh chart

Strongest Trends Summary For CARA

CARA is in the medium-term up 53% in 1 year. In the long-term up 198% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase II clinical trials for the treatment acute postoperative pain in adult patients. The company is also developing Oral CR845 that has completed Phase I clinical trial for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial for treating neuropathic and inflammatory pain. Cara Therapeutics, Inc. was founded in 2004 and is based in Shelton, Connecticut.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding27.28 M EPS-2.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -49.06% Sales Growth - Q/Q-46.5% P/E-6.79
P/E To EPS Growth P/S38.79 P/BV2.85 Price/Cash Per Share
Price/Free Cash Flow ROA-36.88% ROE-40.17% ROI
Current Ratio14.31 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin-555.3% Net Profit Margin-546.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-10 K Cash From Operating Activities-5.24 M Gross Profit
Net Profit-4.69 M Operating Profit-4.72 M Total Assets51.65 M Total Current Assets49.06 M
Total Current Liabilities3.43 M Total Debt800 K Total Liabilities4.23 M Total Revenue490 K
Technical Data
High 52 week23.95 Low 52 week11.6 Last close19.03 Last change-0.68%
RSI46.55 Average true range0.99 Beta1.6 Volume1.26 M
Simple moving average 20 days0.06% Simple moving average 50 days0.02% Simple moving average 200 days4.44%
Performance Data
Performance Week1.17% Performance Month5.31% Performance Quart11.61% Performance Half0.69%
Performance Year53.47% Performance Year-to-date46.38% Volatility daily2.89% Volatility weekly6.46%
Volatility monthly13.24% Volatility yearly45.87% Relative Volume252.99% Average Volume692.03 K
New High New Low

News

2019-09-19 10:11:28 | How Much Of Cara Therapeutics, Inc. NASDAQ:CARA Do Institutions Own?

2019-08-21 16:24:33 | Cara Therapeutics Inc CARA Q2 2019 Earnings Call Transcript

2019-08-21 11:44:43 | 10 Marijuana Stocks That Could See 100% Gains, If Not More

2019-08-21 07:04:00 | Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

2019-08-21 07:00:00 | Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

2019-08-19 12:34:11 | Does Cara Therapeutics, Inc.'s NASDAQ:CARA CEO Pay Reflect Performance?

2019-08-08 05:37:56 | Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-05 10:21:00 | Here's Why Cara Therapeutics Rose 11.3% in July

2019-08-05 07:21:00 | Only These 9 Cannabis Stocks Rose in July

2019-07-31 16:01:00 | Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

2019-07-29 16:01:00 | Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-07-26 21:18:00 | Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment

2019-07-25 11:59:00 | Cara Therapeutics Floats New Stock Issue

2019-07-24 20:42:45 | Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

2019-07-24 16:01:00 | Cara Therapeutics Announces Proposed Offering of Common Stock

2019-07-22 07:00:00 | Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

2019-07-17 19:15:03 | Cara Therapeutics Inc CARA CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares

2019-07-16 10:28:34 | 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts

2019-07-14 07:30:00 | 3 Top Biotech Stocks to Buy for the 2nd Half of 2019

2019-07-13 07:56:07 | Estimating The Fair Value Of Cara Therapeutics, Inc. NASDAQ:CARA

2019-07-12 18:27:33 | GuruFocus Value Idea Contest Sees 2 Winners!

2019-07-11 08:30:00 | Enteris BioPharma's _Feasibility-to-Licensing_ Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

2019-07-09 07:00:00 | Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ CR845/difelikefalin for Pruritus in Patients with Atopic Dermatitis

2019-07-02 07:16:00 | Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

2019-06-26 07:00:00 | Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA?? CR845/difelikefalin for Pruritus in Patients with Primary Biliary Cholangitis PBC

2019-06-02 09:09:00 | Is Cara Therapeutics a Buy Now?

2019-05-31 07:00:00 | Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference

2019-05-30 07:48:11 | Cara Shares Up on Positive Phase III Data for Itchiness Drug

2019-05-29 14:30:00 | Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment

2019-05-29 13:13:47 | Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more

2019-05-29 11:48:56 | Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug

2019-05-29 11:36:08 | Why Cara Therapeutics Stock Is Soaring Today

2019-05-29 10:39:55 | Understanding Medical Cannabis vs. Recreational Cannabis Stocks

2019-05-29 09:36:06 | Announcing: Cara Therapeutics NASDAQ:CARA Stock Increased An Energizing 193% In The Last Three Years

2019-05-29 09:23:00 | Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment

2019-05-29 09:02:00 | Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment

2019-05-29 07:00:00 | Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

2019-05-29 06:00:00 | 3 Top Small-Cap Stocks to Buy Right Now

2019-05-28 10:43:12 | 3 ‘Strong Buy’ Cannabis Biotech Stocks To Know Now

2019-05-23 07:10:39 | Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use

2019-05-17 06:00:00 | 3 Small-Cap Biotech Stocks You Can Buy Right Now

2019-05-09 13:12:06 | Did Hedge Funds Drop The Ball On Casa Therapeutics Inc CARA ?

2019-05-08 23:12:49 | Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-08 16:01:00 | Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

2019-05-08 14:23:30 | Cara Therapeutics Inc CARA Q1 2019 Earnings Call Transcript

2019-05-07 18:25:10 | Cara Therapeutics CARA Reports Q1 Loss, Lags Revenue Estimates

2019-05-07 17:15:25 | Cara: 1Q Earnings Snapshot

2019-05-07 16:01:00 | Cara Therapeutics Reports First Quarter 2019 Financial Results

2019-05-07 13:20:02 | Key Cannabis Sector Updates: Analyst Ratings and Earnings

2019-05-07 11:45:50 | Cannabis Stocks Had a Mixed Performance Last Week